https://www.selleckchem.com/products/pyr-41.html
Patients who received any cirAE treatment had improved progression-free survival [hazard ratio (HR) 0·59, P=0·001] and overall survival (HR 0·58, P=0·007) compared with those who did not. CirAEs evaluated by dermatologists were significantly more likely to be treated than cirAEs that were not referred, and patients who received any treatment for a cirAE had improved survival outcomes. CirAEs evaluated by dermatologists were significantly more likely to be treated than cirAEs that were not referred, and patients who received any treatment